{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:29:56Z","timestamp":1771399796067,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008221","name":"Braile Biom\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The durability of aortic bioprostheses remains limited by progressive tissue calcification, the main mechanism underlying structural valve deterioration. Aiming to mitigate this process, the VIVERE\u00ae Biological Heart Valve Prosthesis, treated with the REALOG\u00ae anticalcification technology, was developed to reduce degenerative effects associated with glutaraldehyde fixation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, clinical performance, and hemodynamic outcomes of the VIVERE\u00ae Biological Heart Valve Prosthesis over 36 months following aortic valve replacement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective, multicenter, single-arm study included patients with aortic valve disease who underwent valve replacement using VIVERE\u00ae bioprosthesis. Clinical success (valve implantation without complications and no major adverse event until hospital discharge), linearized rates of major adverse events\u2014composite and valve-related (death and\/or stroke and\/or reintervention), survival, clinical efficacy (NYHA class I\u2013II), and hemodynamic performance (valve area, mean gradient, and presence of regurgitation or paravalvular leak) were assessed. Follow-up was conducted for up to 36 months after implantation. Continuous variables were expressed as mean\u2009\u00b1\n                      <jats:sans-serif>\u2009standard<\/jats:sans-serif>\n                      deviation, and categorical variables as frequencies and percentages. Survival was assessed by Kaplan\u2013Meier analysis, and linearized event rates expressed per 100 patient-years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>106 patients were included, with a mean age of 67\u2009\u00b1\u200911.6 years. Clinical success was observed in 88.7% of patients, with a linearized rate of valve-related major adverse composite events of 1.0% per patient-year and a 36-month survival of 87.7%. At 36 months, there was an 80% reduction in mean gradient and a 71% increase in effective orifice area, with 87.5% of patients in NYHA functional class I\u2013II. No structural valve deterioration or paravalvular leak was observed at 36 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At 36 months, VIVERE\u00ae demonstrated favorable valve-related safety and efficacy, with low valve-related mortality, stable hemodynamics, and sustained functional improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1765211","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:55:44Z","timestamp":1771397744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["VITTA TRIAL \u2013 safety and performance at 3-year follow-up after implantation of the VIVERE\u00ae aortic bioprosthesis"],"prefix":"10.3389","volume":"13","author":[{"given":"Luiz Carlos","family":"Bettiati Junior","sequence":"first","affiliation":[{"name":"Hospital De Caridade S\u00e3o Vicente De Paulo","place":["Jundia\u00ed, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davi Jean Buoro","family":"Cassano","sequence":"additional","affiliation":[{"name":"Hospital De Caridade S\u00e3o Vicente De Paulo","place":["Jundia\u00ed, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Eduardo","family":"Gullo","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora (Funda\u00e7\u00e3o Pio XII)","place":["Barretos, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Carlos Ferreira","family":"Leal","sequence":"additional","affiliation":[{"name":"Hospital Benefic\u00eancia Portuguesa","place":["S\u00e3o Jos\u00e9 do Rio Preto, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/medsci10020032","article-title":"Valvular heart disease epidemiology","volume":"10","author":"Aluru","year":"2022","journal-title":"Med Sci (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"Guidelines for the management of valvular heart disease","volume":"46","author":"Praz","year":"2025","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ijcp.12471","article-title":"Aortic valve disease","volume":"68","author":"Rayner","year":"2014","journal-title":"Int J Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2022.08.787","article-title":"National trends in TAVR and SAVR for patients with severe isolated aortic stenosis","volume":"80","author":"Sharma","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jtcvs.2019.05.081","article-title":"Surgical valve selection in the era of transcatheter aortic valve replacement in the society of thoracic surgeons database","volume":"159","author":"Tam","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e018506","DOI":"10.1161\/JAHA.120.018506","article-title":"Degeneration of bioprosthetic heart valves: update 2020","volume":"9","author":"Kostyunin","year":"2020","journal-title":"JAHA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36688","DOI":"10.31083\/RCM36688","article-title":"Mechanistic insights into bioprosthetic heart valve calcification and anti-calcification strategies","volume":"26","author":"Yang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21470\/1678-9741-2020-0635","article-title":"Bioprosthetic aortic valve degeneration: a review from a basic science perspective","volume":"37","author":"Velho","year":"2022","journal-title":"Braz J Cardiovasc Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"909801","DOI":"10.3389\/fphar.2022.909801","article-title":"Mechanisms and drug therapies of bioprosthetic heart valve calcification","volume":"13","author":"Wen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41591-022-01682-w","article-title":"The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration","volume":"28","author":"Senage","year":"2022","journal-title":"Nat Med"},{"key":"B11","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E482","DOI":"10.1111\/aor.13718","article-title":"In vivo evaluation of vivere bovine pericardium valvular bioprosthesis with a new anti-calcifying treatment","volume":"44","author":"Braile-Sternieri","year":"2020","journal-title":"Artif Organs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1525-1594.2011.01262.x","article-title":"In vitro properties and performance of glutaraldehyde-crosslinked bovine pericardial bioprostheses treated with glutamic acid","volume":"35","author":"Braile","year":"2011","journal-title":"Artif Organs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e20240405","DOI":"10.21470\/1678-9741-2024-0405","article-title":"Long-Term safety and performance of a national pericardium organic valvular bioprosthesis in the Brazilian public health system: retrospective analysis up to 26 years of follow-up","volume":"40","author":"Ardito","year":"2025","journal-title":"Braz J Cardiovasc Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e20230015","DOI":"10.21470\/1678-9741-2023-0015","article-title":"Safety, effectiveness, and hemodynamic performance of the bovine pericardium organic valvular bioprosthesis","volume":"38","author":"R\u00f6sler","year":"2023","journal-title":"Braz J Cardiovasc Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.athoracsur.2007.12.082","article-title":"Guidelines for reporting mortality and morbidity after cardiac valve interventions","volume":"85","author":"Akins","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"B17","volume-title":"Cardiovascular Implants \u2014 cardiac Valve Prostheses","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s11748-020-01566-1","article-title":"Comparison of safety and haemodynamic performance between the avalus\u2122 stented aortic valve bioprosthesis and Magna\u2122 valve in Japanese patients","volume":"69","author":"Tadokoro","year":"2021","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1111\/jocs.17140","article-title":"Eight-year outcomes of aortic valve replacement with the Carpentier-Edwards PERIMOUNT Magna ease valve","volume":"37","author":"Tsui","year":"2022","journal-title":"J Card Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1393762","DOI":"10.3389\/fcvm.2024.1393762","article-title":"Three-year outcomes of surgical valve replacement with dafodil\u2122 pericardial bioprosthesis: dafodil\u2122-1 trial","volume":"11","author":"Hiremath","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B21","volume-title":"Delivering Quality Health Services: A Global Imperative","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e64790","DOI":"10.1371\/journal.pone.0064790","article-title":"Differences in sepsis treatment and outcomes between public and private hospitals in Brazil: a multicenter observational study","volume":"8","author":"Conde","year":"2013","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4021\/jocmr1157w","article-title":"Difference in patient outcomes coming from public and private hospitals in an intensive care unit in Brazil","volume":"4","author":"Amorim","year":"2012","journal-title":"J Clin Med Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ejcts\/ezs043","article-title":"EuroSCORE II","volume":"41","author":"Nashef","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12872-017-0725-9","article-title":"Medium-term outcomes of 78,808 patients after heart valve surgery in a middle-income country: a nationwide population-based study","volume":"17","author":"de Aquino Xavier","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.21470\/1678-9741-2019-0408","article-title":"Valve heart surgery in Brazil - the BYPASS registry analysis","volume":"35","author":"Zilli","year":"2020","journal-title":"Braz J Cardiovasc Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1161\/CIRCULATIONAHA.113.005220","article-title":"Endocarditis in congenital heart disease: who is at highest risk?","volume":"128","author":"Mulder","year":"2013","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/jpm15090410","article-title":"Long-term outcomes in aortic stenosis: mortality analysis in a selected patient group","volume":"15","author":"Irtyuga","year":"2025","journal-title":"JPM"},{"key":"B29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/icvts\/ivab016","article-title":"Magna ease bioprosthetic aortic valve: mid-term haemodynamic outcomes in 1126 patients","volume":"32","author":"Thorp","year":"2021","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"ezac374","DOI":"10.1093\/ejcts\/ezac374","article-title":"Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes","volume":"62","author":"Klautz","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"ezae414","DOI":"10.1093\/ejcts\/ezae414","article-title":"Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis","volume":"67","author":"Sabik","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ejcts\/ezx158","article-title":"The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue","volume":"52","author":"Puskas","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.athoracsur.2021.12.058","article-title":"Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue","volume":"115","author":"Bavaria","year":"2023","journal-title":"Ann Thorac Surg"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1765211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:55:45Z","timestamp":1771397745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1765211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1765211"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1765211","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1765211"}}